Skip to main content
icon for Quem Trump anunciará como próximo comissário da FDA?

Quem Trump anunciará como próximo comissário da FDA?

icon for Quem Trump anunciará como próximo comissário da FDA?

Quem Trump anunciará como próximo comissário da FDA?

Kyle Diamantas 52%

Stephen Hahn 7%

Brett Giroir 3.9%

Sara Brenner 3.3%

Polymarket
NOVO

Kyle Diamantas 52%

Stephen Hahn 7%

Brett Giroir 3.9%

Sara Brenner 3.3%

Polymarket
NOVO

Kyle Diamantas

$1,515 Vol.

52%

Stephen Hahn

$975 Vol.

7%

Brett Giroir

$1,510 Vol.

4%

Grace Graham

$1,842 Vol.

3%

Sara Brenner

$848 Vol.

3%

No announcement by December 31

$425 Vol.

1%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas, the agency's Deputy Commissioner for Food now serving as acting head, to frontrunner status in trader pricing. Trump's direct Truth Social endorsement of Diamantas for the interim role, combined with his legal-policy background and ties to administration figures, has concentrated market expectations around a permanent nomination for him. Former Commissioner Stephen Hahn and ex-acting head Brett Giroir remain distant alternatives due to prior service records, while Sara Brenner and Grace Graham trail on limited public signals. The low probability assigned to no announcement by year-end reflects the administration's ongoing search for a confirmed successor amid standard Senate confirmation processes.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$6,959
Data de Término
31 dez 2026
Mercado Aberto
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas, the agency's Deputy Commissioner for Food now serving as acting head, to frontrunner status in trader pricing. Trump's direct Truth Social endorsement of Diamantas for the interim role, combined with his legal-policy background and ties to administration figures, has concentrated market expectations around a permanent nomination for him. Former Commissioner Stephen Hahn and ex-acting head Brett Giroir remain distant alternatives due to prior service records, while Sara Brenner and Grace Graham trail on limited public signals. The low probability assigned to no announcement by year-end reflects the administration's ongoing search for a confirmed successor amid standard Senate confirmation processes.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$6,959
Data de Término
31 dez 2026
Mercado Aberto
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

Cuidado com os links externos.

Frequently Asked Questions

"Quem Trump anunciará como próximo comissário da FDA?" is a prediction market on Polymarket with 6 possible outcomes where traders buy and sell shares based on what they believe will happen. The current leading outcome is "Kyle Diamantas" at 52%, followed by "Stephen Hahn" at 7%. Prices reflect real-time crowd-sourced probabilities. For example, a share priced at 52¢ implies that the market collectively assigns a 52% chance to that outcome. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

"Quem Trump anunciará como próximo comissário da FDA?" is a newly created market on Polymarket, launched on May 13, 2026. As an early market, this is your opportunity to be among the first traders to set the odds and establish the market's initial price signals. You can also bookmark this page to track volume and trading activity as the market gains traction over time.

To trade on "Quem Trump anunciará como próximo comissário da FDA?," browse the 6 available outcomes listed on this page. Each outcome displays a current price representing the market's implied probability. To take a position, select the outcome you believe is most likely, choose "Yes" to trade in favor of it or "No" to trade against it, enter your amount, and click "Trade." If your chosen outcome is correct when the market resolves, your "Yes" shares pay out $1 each. If it's incorrect, they pay out $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current frontrunner for "Quem Trump anunciará como próximo comissário da FDA?" is "Kyle Diamantas" at 52%, meaning the market assigns a 52% chance to that outcome. The next closest outcome is "Stephen Hahn" at 7%. These odds update in real-time as traders buy and sell shares, so they reflect the latest collective view of what's most likely to happen. Check back frequently or bookmark this page to follow how the odds shift as new information emerges.

The resolution rules for "Quem Trump anunciará como próximo comissário da FDA?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.